Factor Xla and tissue factor activity in patients with coronary artery disease

Thrombosis and Haemostasis

Volumn 99, Issue 1, 2008, Pages 142-149

  Butenas, Saulius ^a   Undas, Anetta ^b   Gissel, Matthew T ^a   Szuldrzynski, Konstanty ^b   Zmudka, Krzysztof ^b   Mann, Kenneth G ^a  

^a UNIVERSITY OF VERMONT   (United States)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Coagulation markers; Coronary artery disease; Factor XIa; Inflammation markers; Tissue factor

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD CLOTTING FACTOR 11A; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; MONOCLONAL ANTIBODY; THROMBOPLASTIN; TRANSACTIVATOR PROTEIN; ANTITHROMBIN III; ANTITHROMBIN III PROTEASE COMPLEX; ANTITHROMBIN III-PROTEASE COMPLEX; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 10A; IL6 PROTEIN, HUMAN; PEPTIDE HYDROLASE; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BLOOD CLOTTING TEST; BLOOD CLOTTING TIME; BLOOD SAMPLING; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; FEMALE; HEART INFARCTION; HUMAN; HYPERTENSION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; STABLE ANGINA PECTORIS; ANGINA PECTORIS; BLOOD; BLOOD CLOTTING; CASE CONTROL STUDY; METABOLISM; MIDDLE AGED;

ACUTE CORONARY SYNDROME; AGED; ANGINA PECTORIS; ANTITHROMBIN III; BIOLOGICAL MARKERS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; FACTOR XA; HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PEPTIDE HYDROLASES; THROMBOPLASTIN;

EID: 38349147285     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH07-08-0499     Document Type: Article

References (41)

1. Worthley SG, Osende JI, Helft G, et al. Coronary artery disease: pathogenesis and acute coronary syndromes. Mt Sinai J Med 2001; 68: 167-181.
2. Carter AM. Inflammation, thrombosis and acute coronary syndromes. Diab Vase Dis Res 2005; 2: 113-121.
3. Manten A, de Winter RJ, Minnema MC, et al. Procoagulant and proinflammatory activity in acute coronary syndromes. Cardiovasc Res 1998; 40: 389-395.
4. Cesari M, Penninx BW, Newman AB, et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 2003; 108: 2317-2322.
5. Bevilacqua MP, Pober JS, Majeau GR, et al. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Nad Acad Sci USA 1986; 83: 4533-4537.
6. Steffel J, Luscher TF, Tanner FC. Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation 2006; 113: 722-731,
7. Ehlers R, Buttcher E, Eltzschig HK, et al. Correlation between ST-T-segment changes with markers of hemostasis in patients with acute coronary syndromes. Cardiology 2002; 98: 40-45.
8. LiYH, Teng JK, Tsai WC, et al. Prognostic significance of elevated hemostatic markers in patients with acute myocardial infarction. J Am Coll Cardiol 1999; 33: 1543-1548.
9. MorangePE, Bickel C, Nicaud V, et al. Haemostatic factors and the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study. Arterioseler Thromb Vase Biol 2006; 26: 2793-2799.
10. Derhaschnig U, Laggner AN, Roggla M, et al. Evaluation of coagulation markers for early diagnosis of acute coronary syndromes in the emergency room. Clin Chem 2002; 48: 1924-1930.
11. Morange PE, Blankenberg S, Alessi MC, et al. Prognostic value of plasma tissue factor and tissue factor pathway inhibitor for cardiovascular death in patients with coronary artery disease: the AtheroGene study. J Thromb Haemost 2007; 5: 475-482.
12. van der Putten RF, te Velthuis HT, de Zwaan C, et al. State and diagnostic value of plasma tissue factor in early-hospitalised patients with chest pain. Br J Haematol 2005; 131: 91-99.
13. Campo G, Valgimigli M, Ferraresi P, et al. Tissue factor and coagulation factor VII levels during acute myocardial infarction: association with genotype and adverse events. Arterioscler Thromb Vase Biol 2006; 26: 2800-2806.
14. Minnema MC, Peters RJ, de Winter R, et al. Activation of clotting factors XI and IX in patients with acute myocardial infarction. Arterioscler Thromb Vase Biol 2000; 20: 2489-2493.
15. Scott CF, Schapira M, James HL, et al. Inactivation of factor XIa by plasma protease inhibitors: predominant role of alpha I-protease inhibitor and protective effect of high molecular weight kininogen. J Clin Invest 1982; 69: 844-852.
16. Wuillemin WA, Minnema M, Meijers JC, et al. Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: major role for C1-inhibitor. Blood 1995; 85: 1517-1526.
17. Cawthern KM, van't Veer C, Lock JB, DiLorenzo ME, Branda RF, Mann KG. Blood coagulation in hemophilia A and hemophilia C. Blood 1998; 91: 4591-4592.
18. Higgins DL, Mann KG. The interaction of bovine factor V and factor V-derived peptides with phospholipid vesicles. J Biol Chem 1983; 258: 6503-6508.
19. Butenas S, Dee JD, Mann KG. The function of factor XI in tissue factor-initiated thrombin generation. J Thromb Haemost 2003; 1: 2103-2111.
20. Parhami-Seren B, Butenas S, Krudysz-Amblo J, Mann KG. Immunologic quantitation of tissue factors. J Thromb Haemost 2006; 4: 1747-1755.
21. Colman RW, Clowes AW, George JN, et al. Overview of hemostasis. In: Hemostasis and thrombosis basic principles and clinical practice. Lippincott Williams & Wilkins, 2006: 3-16.
22. Gailani D, Broze GJ, Jr. Factor XI activation in a revised model of blood coagulation. Science 1991; 253: 909-912.
23. Ratnoff OD, Coply JE. A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma. J Clin Invest 1955; 34: 602-613.
24. Halbmayer WM, Mannhalter C, Feichtinger C, et al. Factor XII (Hageman factor) deficiency: a risk factor for development ofthromboembolism. Incidence of factor XII deficiency in patients after recurrent venous or arterial thromboembolism and myocardial infarction. Wien Med Wochenschr 1993; 143: 43-50.
25. Goodnough LT, Saito H, Ratnoff OD. Thrombosis or myocardial infarction in congenital clotting factor abnormalities and chronic thrombocytopenias: a report of 21 patients and a review of 50 previously reported cases. Medicine (Baltimore) 1983; 62: 248-255.
26. Zito F, Lowe GD, Rumley A, et al. Association of the factor XII 46C>T polymorphism with risk of coronary heart disease (CHD) in the WOSCOPS study. Atherosclerosis 2002; 165: 153-158.
27. Colhoun HM, Zito F, Norman CN, et al. Activated factor XII levels and factor XII 46C>T genotype in relation to coronary artery calcification in patients with type 1 diabetes and healthy subjects. Atherosclerosis 2002; 163: 363-369.
28. Renne T, Pozgajova M, Gruner S, et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 2005; 202: 271-281.
29. Kleinschnitz C, Stoll G, Bendszus M, et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med 2006; 203: 513-518.
30. Cooper JA, Miller GJ, Bauer KA, et al. Comparison of novel hemostatic factors and conventional risk factors for prediction of coronary heart disease. Circulation 2000; 102: 2816-2822.
31. Lowe GD, Rumley A, McMahon AD, et al. Interleukin-6, fibrin D-dimer, and coagulation factors VII and XIIa in prediction of coronary heart disease. Arterioscler Thromb Vasc Biol 2004; 24: 1529-1534.
32. Altieri P, Devoto E, Spallarossa P, et al. Acute coronary syndromes do not promote prolonged in vivo FXII-dependent prothrombotic activity. Thromb Res 2005; 115: 65-72.
33. Grignani G, Maiolo A. Cytokines and hemostasis. Haematologica 2000; 85: 967-972.
34. Pedicord DL, Seiffert D, Blat Y. Feedback activation of factor XI by thrombin does not occur in plasma. Proc Natl Acad Sci USA 2007; 104: 12855-12860.
35. Morrissey JH, Macik BG, Neuenschwander PF, et al. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 734-744.
36. Butenas S, Orfeo T, Brummel-Ziedins KE, Mann KG. Membrane-bound and soluble tissue factor - fuse and fire extinguisher. Blood 2004; 104: Abstract 39a.
37. del Conde I, Shrimpton CN, Thiagarajan P, et al. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood 2005; 106: 1604-1611.
38. Osterud B, Bjorklid E. Sources of tissue factor. Semin Thromb Hemost 2006; 32: 11-23.
39. Simak J, Gelderman MP. Cell membrane microparticles in blood and blood products: potentially pathogenic agents and diagnostic markers. Transfus Med Rev 2006; 20: 1-26.
40. Wuillemin WA, Hack CE, Blecker WK, et al. Inactivation of factor XIa in vivo: studies in chimpanzees and in humans. Thromb Haemost 1996; 76: 549-555.
41. Holmes MB, Schneider DJ, Hayes MG, et alG. Novel, bedside, tissue factor-dependent clotting assay permits improved assessment of combination antithrombotic and antiplatelet therapy. Circulation 2000; 102: 2051-2057.